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Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) 
translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% 
of all non-Hodgkin's lymphomas. Mantle cell lymphoma generally affects patients over 60 years-old. 
Most patients have advanced disease (>70 % Ann Arbor stage IV). Several efforts have been made to 
predict outcome in mantle cell lymphoma. The cell-proliferation marker Ki-67, the Mantle Cell Lymphoma 
International Prognostic Index, fluorodeoxyglucose positron emission tomography and minimal residual 
disease are prognostic tools. For young patients, chemoimmunotherapy followed by high-dose chemo-
therapy plus stem cell transplantation is the treatment of choice. For the main group of older patients, 
chemo-immunotherapy followed by maintenance with rituximab is the gold standard. In relapses, temsi-
rolimus is actually registered and new drugs, such as ibrutinib, are currently evaluated with promising 
preliminary results.2-5
(Belg J Hematol 2014;5(3):89-96)
Epidemiology
In the United States, during the thirteen-year period 
between 1992 and 2004, the overall incidence of 
mantle cell lymphoma (MCL) (per 100,000) was 0.55, 
which increased with age: 0.07 in patients aged <50 
years, 2.97 in patients aged 70-79 years, and 2.78 in 
those aged >80 years. The median age at diagnosis 
was 68 years. The incidence of MCL was higher in men 
(0.84 of 100,000) than in women (0.34 of 100,000) 
(P < .05). Late-stage (III-IV) MCL was diagnosed in 
 
74.6% of patients.6 Incidence trends of mantle cell 
lymphoma in the United States between 1992 and 2004.
Prognostic factors 
Histological characteristics are important, with a 
more aggressive clinical course for the blastoid and 
pleomorphic variants. The cell-proliferation marker 
Ki-67 has high prognostic relevance: a high index of 
Ki-67 indicates an aggressive disease.7,8 Unfortunately, 
Practice Guidelines
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this tool is not available in daily clinical practice and 
lacks reproducibility.
The Mantle Cell Lymphoma International Prognostic 
Index (MIPI) is a recently established clinical and 
biological score for pre-treatment risk assessment in 
patients with advanced-stage MCL. MIPI is based on 
four independent prognostic factors: age, performance 
status, lactate dehydrogenase and leukocyte count. This 
score, based on data of 455 advanced stage MCL patients, 
defines three groups of patients with different prognoses: 
high risk (HR) (MIPI >= 6,2; 21% of  patients, 5-year 
OS 29%), intermediate risk (IR) (MIPI between 5,7 and 
6,2; 35% of patients; 5-year OS 51%) and low risk (LR) 
(MIPI <5,7; 44% patients, 5-year OS 60%) (Table 1). 
The simplified MIPI (MIPIs) (each variable gives 0 to 3 
points, LR if 3 points, IR if 4 or 5 points and HR if 
more than 5 points) has high concordance with MIPI.9
Minimal residual disease (MRD) is probably the most 
important prognostic factor. The targets for molecular 
monitoring of MRD by real time quantitative polymerase 
chain reaction (RQ-PCR) are clonal IGH VH-JH and 
t(11;14) translocation. Retrospective data showed that 
quantitative measurement of MRD during and after 
treatment is an early and strong predictor of clinical 
outcome and can define subgroups with a significantly 
different prognosis.10 
Practice Guidelines
Table 1. MIPI score.
Risk MIPI % of patients 5-year OS




LR <5.7 44% 60%
MIPI score is calculated as [0.03535 × age (years)] + 0.6978 (if ECOG > 1) + [1.367 × log
10 
(LDH/ULN)] + [0.9393 × log
10 
(WBC count].
Table 2. Guidelines of the BHS: treatment recommendation for mantle cell lymphoma in Belgium.
Overall recommendations Category*
• Inclusion in a clinical trial is advised given the disappointing results of standard management
First line
• Young patients : R-chemotherapy with high dose cytarabine followed by high dose chemotherapy and ASCT I
• Old patients: R-CHOP21 X 8 followed by Rituximab maintenance I
Salvage
• R-chemo (R-Benda, R-DHAP, R-ICE) in second line II  
• Bortezomib II
• Temsirolimus in third line I
*cfr Table 3
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A molecular remission is defined by a MRD negativity 
of at least 10-4. Pott et al reviewed 259 cases of MCL 
patients treated in two prospective MCL network trials 
and concluded that achieving a molecular response 
after induction independently improves remission 
duration in comparison with patients with residual 
disease.11 Similar results have been shown in the CAL-
BG 559909 study.12 MRD is also an excellent tool 
to quantitatively determine the impact of different 
treatments on tumour clearance, probably better than 
clinical and morphological complete response.11 How-
ever, this interesting tool is not yet routinely available. 
Initial work-up
The initial evaluation should include a clinical exami-
nation, laboratory tests (LDH, circulating tumour cells, 
hepatitis and HIV serologies), contrast-enhanced chest/
abdominal/pelvic CT scan and a bone marrow biopsy 
with cytogenetics. A lymph node biopsy with cyclin D1 
evaluation is also warranted. As digestive localisations 
are frequent, an endoscopic evaluation is recommended 
in case of symptoms.
Only few small retrospective studies are available about 
fluorodeoxyglucose positron emission tomography 
(FDG-PET) in MCL. At initial staging, compared to 
conventional imaging, FDG-PET allows detection of 
additional nodal and extranodal sites but is not more 
sensitive for bone marrow and gastrointestinal tract 
involvement detection. Usually, it does not upgrade the 
Ann Arbor staging.13,14 The SUV max value at the time 
of diagnosis seems to be relevant: there is a trend for 
better outcome in terms of EFS and OS for patients with 
initial SUV max <5 or 6, depending on studies.14,15
First-line therapy
Localised disease
For the small proportion of patients with limited-stage 
disease (10% MCL), radiotherapy (RT) is the preferred 
treatment. A small retrospective study showed an 
improved progression free survival (PFS) (5 years-PFS 
68% versus 11%) and a trend towards improved OS for 
patients treated with regimens including RT.16 
Advanced disease
Transplant-eligible patients 
Conventional R-CHOP-based therapy usually achieves 
high response rates but with short remission durations. 
Most patients finally relapse. A different induction 
chemotherapy and consolidation are thus necessary to 
improve clinical outcome.    
Myeloablative consolidation with autologous stem cell
transplantation
In 2005, Dreyling et al demonstrated in a randomised 
trial that early consolidation by myeloablative radio-
chemotherapy followed by autologous stem cell trans-
plantation (ASCT) in first remission after an initial 
CHOP induction significantly prolongs PFS of young 
and fit patients with advanced stage of MCL (median 
of 39 months in the ASCT arm versus 17 months in 
the conventional (IFN alpha maintenance) arm (p = 
0.0108)).17
High dose cytarabine (HAra-C) 
Growing evidence suggests that HAra-C is probably an 
important drug in the treatment of MCL. Regimens 
with HAra-C were recently used with success in young 
patients: they improved the rate, the quality and the 
duration of response but at the expense of higher toxicity. 
In a phase II study with R-HyperCVAD alternated 
with high dose of methotrexate and cytarabine in first 
line treatment of 97 patients, the MD Anderson group 
showed 97% of response with 87% of complete response 
(CR) or unconfirmed CR (CRu). With a median follow-
up time of 40 months, the 3-year event-free survival 
(EFS) and OS rates were 64% and 82%, respectively.18 
Based on the superiority of ASCT after conventional 
chemotherapy induction and the efficacy of HAra-C 
regimens, the GELA trial assessed the potential 
benefit of the combination of HAra-C containing 
chemoimmunotherapy followed by ASCT with very 
good results.19 In another Nordic trial, 160 untreated 
young patients were included in a phase II protocol 
with dose-intensified induction chemoimmunotherapy 
with R-maxi-CHOP, alternating with R + HAra-C 
followed by high dose chemotherapy + ASCT. OR 
and CR was achieved in 96% and 54%, respectively.20
A large prospective, multicentre, randomised phase III 
study of the European MCL network with 500 young 
patients (median age 55 years) showed that in com-
parison with R-CHOP + ASCT, a regimen containing 
HAra-C alternating with R-CHOP + ASCT increases 
significantly CR/CRu rates (40 versus 54 %, p= 0,003) 
and TTF (46 versus 88 months, p= 0.038) without 
clinically relevant increase in toxicity.21 An induction 
treatment with four cycles of R-DHAP (dexamethasone, 
cytarabine and cisplatin) was evaluated in the LyMa 
trial. Based on preliminary results, induction with R-
DHAP is probably better than alternating R-CHOP with 
R-DHAP (76,3% CR/CRu after four cycles R-DHAP).22 
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In case of renal impairment, oxaliplatin can be used 
instead of cisplatin.  
Maintenance
The interest of R maintenance after immunochemo-
therapy (4x R-DHAP) followed by ASCT for young 
patients is currently under investigation in the ran-
domised phase III LyMa trial.22
Lenalidomide in maintenance therapy is also being 
studied in an ongoing Italian randomised phase III 
study (MCL 0208).23 
Non transplant-eligible patients 
MCL typically affects patients over 60 years of age and 
more than half of them are elderly. The prognosis of 
elderly patients with MCL is very poor with low rates 
of CR and high rates of rapid recurrences. Clinical trials 
attempt to establish more effective induction therapy 
to improve CR rates, and better post-induction strategies 
to prolong duration of remission.
Fit 
Chemo-immunotherapy 
Results of a first large randomised study in elderly 
MCL patients (560 patients) were recently presented 
by the European MCL network. In comparison with 
R-FC (six cycles, R-FC/28 days), induction therapy 
R-CHOP (eight cycles R-CHOP/21days) is superior in 
terms of ORR (86% versus 78% p= 0.059) and OS 
(4-years OS 62% versus 47%, p=0.005). Furthermore, 
additional toxicities and lower compliance were more 
frequently observed in the R-FC arm.24 
Maintenance
Historically, maintenance consisted of interferon alpha 
treatment (improvement of PFS and OS).25 The recent 
study of the European MCL network demonstrated the 
superiority of R (one dose every two months until 
progression) compared to IFN alpha in maintenance, 
not only in terms of PFS benefit (doubling of duration 
remission for patients who had responded upon induc-
tion therapy), but also in terms of survival for patients 
pre-treated with R-CHOP.24 For elderly untreated 
patients, a modified fractioned hyper-CVAD regimen 
followed by R maintenance improves PFS and OS: the 
proportion of patients surviving at five years is 62%, 
comparable to trials using intensive strategies in simi-
lar patient populations.26
The efficacy of R maintenance depends nevertheless 
on the type of induction regimen. After single agent 
monoclonal antibody therapy, R maintenance does not 
demonstrate a significant benefit in comparison with 
the observational arm.27
Unfit
A palliative or reduced-intensity chemotherapy +/-R is 
indicated if the patient is unable to tolerate aggressive 
treatment. In this setting, chlorambucil could be a 
valuable option with few side effects.28  
Salvage therapy
Despite the advances in front-line regimen (both for 
induction and consolidation/ maintenance), relapses 
still occur. Treatment of relapsed/refractory MCL is 
currently not standardised and a wide variety of sal-
vage strategies are available. Chemotherapies are often 
used in combination with immunotherapy and eventu-
ally followed by R maintenance or consolidation by 
allogeneic stem cell transplantation in highly selected 
cases. We discuss here the use of fludarabine and 
bendamustine because these drugs are predominantly 
Table 3. Categories of evidence level.
• Level I: Evidence obtained from at least one properly designed randomised controlled trial.
• Level II-1: Evidence obtained from well-designed controlled trials without randomisation.
•  Level II-2: Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or research group.
•  Level II-3: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be 
regarded as this type of evidence.
• Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. 
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used in relapses. Neither are licensed nor reimbursed 
in Belgium for this indication. 
Fludarabine  
Fludarabine plus rituximab (F-R) is an established 
treatment option in relapsed/refractory MCL. As report-
ed above, the GLSG explored the combined use of R 
and F-containing regimen in the treatment of recurrent 
and refractory MCL and found that the combination of 
R-FCM (compared with chemotherapy alone) signifi-
cantly improved ORR (58% versus 46%), CR rates 
(29% versus 0.0%) and also OS.29
However, in the setting of relapsed disease, recently 
published results showed that the combination benda-
mustine-rituximab (B-R) is superior to F-R in terms of 
PFS.30 
As for the other molecules, the future for fludarabine 
could be in combination with new drugs. In a small 
phase I study, a response was achieved in 8 of 10 MCL 
patients with R-F-Flavopiridol (CDK inhibitor leading 
to downregulation of cyclin D1).31 
Bendamustine
Based on results of two small phase-II studies, B-R is 
potentially a good option for patients with relapsed/
refractory indolent or mantle cell lymphoma.32,33
A recent large multicentre randomised phase III study 
(StiL) compared the efficacy and safety of B-R versus 
F-R for relapsed follicular, indolent and mantle cell 
lymphomas. Results confirmed the superiority of B-R 
in terms of PFS (30 versus 11 months; p<0.0001), OR 
(83.5% versus 52.5%, p< 0.0001) and CR (38.5% 
versus 16.2%; p=0.0004) but not in terms of OS.30
Targeted approaches
R-chemotherapy is not very satisfactory after relapse. 
This emphasises the need for novel therapies. Based 
on a better knowledge of the MCL pathogenesis, new 
targeted approaches are being developed. 
Ibrutinib
Of particular interest in this situation, the Burton’s 
Tyrosine Kinase-inhibitor (PCI32765-Ibrutinib) is actu-
ally extensively evaluated.34 Good results were recently 
published in a phase II study on 115 relapsed MCL 
patients. The overall response rate was 68% with 21% 
of CR and the median duration of response was 17.5 
months.35 This molecule has recently been approved by 
the Food and Drug Administration (FDA) for relapsing 
mantle cell lymphoma. However, not all targeted drugs 
are currently licensed nor reimbursed in Belgium, except 
temsirolimus for second relapse.
Temsirolimus
MCL is characterised by a t(11;14) resulting in overex-
pression of cyclin D1 messenger RNA. Temsirolimus 
(Tem) selectively inhibits the mammalian target of 
rapamycin (mTOR) kinase that regulates cyclin D1 
translation. With this molecule as a single agent therapy 
(250mg IV every week) for relapsed MCL, RR was 38 %, 
median time-to-progression 6.5 months and the dura-
tion of response 6.9 months.36 A randomised phase III 
study confirms the superiority in terms of PFS of Tem 
(dose 175 mg once weekly for three weeks followed by 
75 mg once weekly) to standard options (investigator's 
choice) in relapsed/refractory MCL.37  
RAD 001 (everolimus), another mTOR antagonist, seems 
to have a better effect in vitro. Its clinical efficacy in 
relapsed MCL is now evaluated (ORR was 20% in a 
multicentre phase II trial with over 35 patients with a 
maximum of three prior lines of chemotherapy).38 
Results are promising for Tem in combination with 
immunotherapy or immunochemotherapy. In a phase 
II study of 71 patients, Tem with R allows 59% ORR, 
with interestingly good results for prior R-refractory 
patients (52% ORR).39 The Tem-B-R association is cur-
rently being studied.23,40  
Bortezomib  
According to the Pinnacle study, bortezomib represents 
a valuable treatment option for patients with relapsed/
refractory MCL (32% RR), including those who have 
relapsed following high-intensity therapy. Moreover, 
toxicity profile is manageable.41 This drug is approved 
for MCL treatment in the US but not in Europe.
Some recent data from a small German multicentre 
observational study suggest synergistic efficacy of 
bortezomib in combination with cytarabine: responses 
were observed in four patients (two CR) of eight heavily 
pre-treated patients who received bortezomib, dexa-
methasone, and HAra-C + R if they were not refrac-
tory to prior R-containing regimens. Median PFS and 
OS were five and 15.5 months, respectively.42 To con-
firm these preliminary results, a randomised, multi-
centre phase III study of the European MCL network 
was launched to compare efficacy and safety of R, 
HAra-C and dexamethasone alone or in combination 
with bortezomib in patients with relapsed or refractory 
mantle cell lymphoma (MCL 2005-01). Synergistic 
effect is also described between proteasome and 
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histone deacetylase (HDAC) inhibitors. Results of a 
small phase II trial presented at the 2011 ASH meeting 
suggest the activity of bortezomib in association with 
the HDAC inhibitor vorinostat in MCL (RR 47 %).43
Lenalidomide
Single-agent
Some phase II trials investigated the efficacy and safety 
of single-agent Lenalidomide (Len) (25 mg once a day 
d1-d21 of a 28 days cycle) in patients with relapsed or 
refractory MCL: it was well tolerated and active (ORR: 
28-53%).44-47
Based on synergistic effects of in vitro observation and 
positive results in myeloma, the combination Len + 
dexamethasone were studied. Results were comparable 
to Len alone but with a possible detrimental effect of 
dexamethasone on the immune activation generated 
by Len.48
In combination
R directly targets CD20 positive lymphoma cells while 
Len targets the microenvironment. Both have single-
agent activity in MCL. This combination is active with 
an ORR of 57 % and a median duration of response of 
18,9 months in the study of Wang.49 The interest of 
treatment with R-Len and bendamustine for refractory/
relapsed MCL is being studied in an ongoing prospec-
tive phase II.23 
Allogeneic stem cell transplantation
In second-line consolidation, alloSCT is an option in 
selected patients with MCL. There are few data about 
the role of alloSCT but good results are obtained for 
relapsed MCL in small studies.50,51 In fact, this approach 
is currently the only potentially curative treatment, 
based on graft versus host disease effect. Its application 
is limited by the important age-dependent mortality 
and co-morbidities. A full-intensity conditioning regimen 
appears too toxic and dose-reduced intensity condi-
tioning (RIC-allo) is probably the best option.52,53
Conclusion
Despite recent advances, MCL remains a challenging 
disease. More effective and new management strategies 
are currently being studied in order to optimise treat-
ment and improve clinical outcome. In this setting, 
precisely defined subgroups of MCL with reliable prog-
nostic tools will be necessary to predict the individual 
course of the disease and to propose the most appro-
priate therapeutic approach.
References
1. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell 
lymphoma. J Clin Invest 2012;22(10):3416-23.
2. Dreyling M, Hiddemann W. Current treatment standards and emerging 
strategies in mantle cell lymphoma. Haematology Am Soc Hematol Educ 
Program 2009;542-51. 
3. Ghielmini M, Zucca E. How I treat Mantle Cell lymphoma. Blood 
2009;114(8):1469-76.
4. Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, 
and clinical management. Am J Hematol 2012;87(6):604-9. 
5. Harel S, Delarue R, Ribrag V, et al.  Treatment of younger patients with mantle 
cell lymphoma. Semin Hematol 2011;48(3):194-207.
6. Zhou Y, Wang H, Fang W,  et al. Incidence trends of mantle cell lymphoma in 
the United States between 1992 and 2004. Cancer 2008;113(4):791-8.
7. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation 
indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): 
a clinicopathological study from the European MCL Network. Br J Haematol 
2005;131(1):29-38.
8. Katzenberger T, Petzoldt C, Höller S, et al. The Ki67 proliferation index is 
a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 
2006;107(8):3407.
9. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for 
patients with advanced-stage mantle cell lymphoma. Blood 2008;111(2):558-65.
10. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular 
remission after high-dose therapy with autologous stem cell transplantation 
predicts long-term remission in mantle cell lymphoma. Blood 2006;107(6):2271-8.
11. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an indepen-
dent predictor of clinical outcome in patients with mantle cell lymphoma after 
combined immunochemotherapy: a European MCL intergroup study. Blood 
2010;115(16):3215-23.
Key messages for clinical practice
1. In young patients: R-chemotherapy including high dose cytarabine followed by high dose chem-
otherapy with autologous stem cell transplantation is standard of care.
2. In old patients: R-chemotherapy with R maintenance is standard of care.
3. New targeted therapies, such as ibrutinib, are promising in relapse.
3Belgian Journal of Hematology   Volume 5, Issue 3, September 2014
95
12. Liu H, Johnson JL, Koval G, et al. Detection of minimal residual disease fol-
lowing induction immunochemotherapy predicts progression free survival in 
mantle cell lymphoma: final results of CALGB 59909. Haematologica 
2012;97(4):579-85.
13. Alavi A, Shrikanthan S, Aydin A, et al. Fluorodeoxyglucose positron emission 
tomography findings in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 
2011;11(3):261-6.
14. Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-
deoxyglucose positron emission tomography in untreated mantle cell lymphoma: 
a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 
2010;37(9):1633-42.
15. Karam M, Ata A, Irish K, et al. FDG positron emission tomography/computed 
tomography scan may identify mantle cell lymphoma patients with unusually 
favourable outcome. Nucl Med Commun 2009;30(10):770-8.
16. Leitch HA, Gacoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell 
lymphoma. Ann Oncol 2003;14(10):1555-61.
17. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative 
radiochemotherapy followed by autologous stem cell transplantation in first 
remission significantly prolongs progression-free survival in mantle-cell lym-
phoma: results of a prospective randomised trial of the European MCL Network. 
Blood 2005;105(7):2677-84.
18. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remis-
sions after treatment of newly diagnosed aggressive mantle-cell lymphoma 
with rituximab plus hyper-CVAD alternating with rituximab plus high-dose 
methotrexate and cytarabine. J Clin Oncol 2005;23(28):7013-23.
19. Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab 
followed by autologous stem cell transplantation in mantle cell lymphoma: a 
phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 
2013;121(1):48-53.
20. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival 
of mantle cell lymphoma after intensive front-line immunochemotherapy with 
in vivo-purged stem cell rescue: a nonrandomised phase 2 multicentre study 
by the Nordic Lymphoma Group. Blood 2008;112(7):2687-93.
21. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3X CHOP 
and 3X DHAP  Plus Rituximab Followed by a high dose ARA-C myeloablative 
regimen and autologous  stem cell transplantation is superior to 6 courses 
CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT 
in Mantle Cell Lymphoma: Results of the MCL Younger trial of the European 
Mantle Cell Lymphoma Network. Blood (ASH Annual Meeting Abstracts) 
2010;116:Abstract 110.
22. Le Gouill S , Callanan M, Macintyre E, et al. Clinical, Metabolic and Molecular 
Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Trans-
plantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, 
a Lysa Study. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 152.
23. Dreyling M, Kluin-Nelemans HC, Bea S, et al. Update on the molecular 
pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th 
annual conference of the European Mantle Cell Lymphoma Network. Leuk Lym-
phoma 2011;52(12):2226-36.
24. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients 
with mantle-cell lymphoma. N Engl J Med 2012;367(6):520-31.
25. Teodorovic I, Pittaluga S, Kluin-Nelemans HC, et al. Efficacy of four different 
regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 
498 other non-Hodgkin's lymphoma subtypes. European Organisation for the 
Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin 
Oncol 1995;13(11):2819-26.
26. Kenkre VP, Long WL, Eickhoff  JC, et al. Maintenance rituximab following 
induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up 
of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 
2011;52(9):1675-80.
27. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab 
given at the standard schedule or as prolonged treatment in patients with 
mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research 
(SAKK). J Clin Oncol 2005;23(4):705-11.
28. Bauwens D, Maerevoet M, Michaux L, et al, Activity and safety of combined 
rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 
2005;131(3):338-40.
29. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a 
combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly 
increases the response rate and prolongs survival as compared with FCM alone 
in patients with relapsed and refractory follicular and mantle cell lymphomas: 
results of a prospective randomised study of the German Low-Grade Lymphoma 
Study Group. Blood 2004;104(10):3064-71.
30. Rummel MJ, Kaiser U, Balser C, et al. Bendamustine Plus Rituximab Versus 
Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and 
Mantle Cell Lymphomas – Final Results of the Randomised Phase III Study NHL 
2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). 
Blood (ASH Annual Meeting Abstracts) 2010;116:Abstract 856.
31. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in 
mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin 
Oncol 2010;28(3):418-23.
32. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is 
effective and has a favourable toxicity profile in the treatment of mantle cell and 
low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23(15):3383-9.
33. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicentre study 
of bendamustine plus rituximab in patients with relapsed indolent B-cell and 
mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(27):4473-9.
34. Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment 
options. Crit Rev Oncol Hematol 2011;80(1):69-86.
35. Wang L, Rule S, Martin P, et al. Targeting BTK with Ibrutinib in relapsed or 
refractory Mantle-cell lymphoma. N Eng J Med, 2013;369(6):507-16.
36. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsiro-
limus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 
2005;23(23):5347-56.
37. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate 
temsirolimus compared with investigator's choice therapy for the treatment of 
relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9.
38. Renner C, Zinzani PL, Gressin R, et al. A multicentre phase II trial (SAKK 
36/06) of single-agent Everolimus (RAD001) in patients with relapsed or refrac-
tory mantle cell lymphoma. Haematologica 2012;97(7):1085-91.
39. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients 
Belgian Journal of Hematology   Volume 5, Issue 3, September 2014
Practice Guidelines
96
with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet 
Oncol 2011;12(4):361-8.
40. Hess G, Keller U, Atta J, et al. Temsirolimus in Combination with Bendamus-
tine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular 
Lymphoma: Report on An Ongoing Phase I/II Trial. Blood (ASH Annual Meeting 
Abstracts) 2011;118:Abstract 2697.
41. Goy A, Bernstein SH, Kahl B, et al. Bortezomib in patients with relapsed 
or refractory mantle cell lymphoma: updated time-to-event analyses of the 
multicentre phase 2 PINNACLE study. Ann Oncol 2009;20(3):520-5.
42. Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high 
dose cytarabine and bortezomib has activity in multiply relapsed and refractory 
mantle cell lymphoma - long-term results of a multicentre observation study. 
Leuk Lymphoma 2009;50(5):716-22.
43. Holkova B, Perkins EB, Sokol L, et al. A Phase II Trial of Bortezomib and 
Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. 
Blood (ASH Annual Meeting Abstracts) 2011;118:Abstract 779.
44. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy 
produces a high response rate in patients with relapsed or refractory mantle cell 
lymphoma. Br J Haematol 2009;145(3):344-9.
45. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in re-
lapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest 
activity and possible gender differences. Br J Haematol 2012;159(2):154-63. 
46. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-
agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's 
lymphoma Ann Oncol 2011;22(7):1622–7.
47. Goy A, Sinha R, Williams ME, et al. Phase II Multicentre Study of Single-
Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or 
Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" 
Study. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 905.
48. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide 
and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical 
results and effects on microenvironment and neo-angiogenic biomarkers. 
Haematologica 2012;97(3):416-22.
49. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination 
with rituximab for patients with relapsed or refractory mantle-cell lymphoma: 
a phase 1/2 clinical trial. Lancet Oncol 2012;13(7):716-23.
50. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell 
transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 
2003;21(23):4407-12.
51. Laudi N, Arora M, Burns L, et al. Efficacy of high-dose therapy and hemato-
poietic stem cell transplantation for mantle cell lymphoma. Am J Hematol 
2006;81(7):519-24.
52. Le Gouill S, Kröger N, Dhedin N, et al. Reduced-intensity conditioning 
allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: 
a multicentre experience. Ann Oncol 2012;23(10):2695-703. 
53. Tam C, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson 
Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. 
Blood 2009;113(18):4144-52.
